[Asia Economy Reporter Minwoo Lee] Biotoxtech's stock price is on the rise. The positive news that the Alzheimer's disease (dementia) treatment developed jointly with Aribio confirmed its efficacy in the FDA-approved Phase 2 clinical trial appears to have acted as a favorable factor.
As of 10:30 AM on the 7th, Biotoxtech's stock price recorded 8,430 KRW, up 6.17% compared to the previous day. The positive impact seems to stem from the news that Aribio, which agreed to jointly develop a dementia treatment since February last year, obtained results showing improved cognitive function in patients during the Phase 2 clinical trial of the dementia treatment AR1001 recently approved by the US FDA.
Aribio conducted the Phase 2 clinical trial of AR1001 over 12 months at 21 clinical centers in the US, confirming the drug's safety and efficacy in 173 patients who completed the first 6-month trial. Subsequently, after additional participant enrollment, an extension trial was conducted on 115 patients who completed 6 months of dosing, revealing that the drug's efficacy was more pronounced than in the earlier phase.
Patients who took AR1001 alone for a total of 12 months scored higher on cognitive function assessment indicators than those who took a placebo: the 10mg dosage group scored 1.6 points higher, and the 30mg dosage group scored 5.8 points higher. Among patients with mild symptoms, where treatment demand is high, the 10mg group improved by 2.2 points, and the 30mg group improved by 8.7 points.
Meanwhile, Biotoxtech began joint development of the dementia treatment with Aribio in February last year.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
